N-PORT filing recap · July 2025

What did ARK Genomic Revolution ETF buy in July 2025?

Reported stock-position changes between this filing and the previous one. These are ARK Genomic Revolution ETF's own holdings, not the firm's.

Stock value

$1.01B

Positions

Estimated turnover

11.1%

Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.

Period in review

ARK Genomic Revolution ETF opened new positions in Ataibeckley and Caris Life Sciences. It trimmed Guardant Health, Natera, 908 Devices, and Veeva Systems, and substantially reduced Adaptive Biotechnologies. The fund also added to Illumina and Prime Medicine, while making smaller increases across several other holdings.

New positions

ATAIAtaibeckley Inc.$6.48Mreported value+1.58M shares CAICaris Life Sciences, Inc.$5.31Mreported value+189.0K shares

Increased positions

TEMTempus Ai, Inc.$89.01Mreported value+42.1K shares+2.7%TXG10x Genomics, Inc.$43.88Mreported value+22.4K shares+0.7%BEAMBeam Therapeutics Inc.$40.17Mreported value+59.0K shares+3.0%PSNLPersonalis, Inc.$38.38Mreported value+230.0K shares

Reduced positions

CRSPCrispr Therapeutics AG$106.50Mreported value-61.9K shares-3.2%TWSTTwist Bioscience Corporation$70.63Mreported value-4.2K shares-0.2%RXRXRecursion Pharmaceuticals, Inc.$68.54Mreported value-258.2K shares-2.2%GHGuardant Health, Inc.$46.89Mreported value-153.1K shares